Central to its near-term growth plan is the performance of Austedo (deutetrabenazine), approved for Huntington’s disease and tardive dyskinesia, which Teva predicts will bring in $2.5 billion in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Teva Pharmaceuticals USA Inc. has made an “arms-length settlement” for $2.7 million to resolve claims that the Israeli pharmaceutical giant misclassified sales specialists as salary-exempt trainees ...

And the best men’s tennis shoes should be durable enough to withstand all that movement. (I learned this when I bought my first pair of tennis shoes — a cheap pair from the mall —when I was ...

Register to read this story and more for free. Signing up for an account helps us improve your browsing experience.

Additionally, Teva reported a significant increase in its second-quarter revenue for 2024, with an 11% growth to $4.2 billion. Piper Sandler reiterated its Overweight rating on shares of Teva ...

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.

Caroline Igo (she/her/hers) is a wellness editor and holds Sleep Science Coach and Stress Management certificates from the Spencer Institute. She received her bachelor's degree in creative writing ...